Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324375395> ?p ?o ?g. }
- W4324375395 abstract "Background Retinopathy of prematurity (ROP) and abnormal brain development share similar risk factors and mechanisms. There has been contrasting evidence on the association of ROP with adverse neurodevelopmental outcomes. Objective We analysed the association between ROP at levels of severity and treatment with all neurodevelopmental outcomes until adolescence. Data source We followed PRISMA guidelines and searched Medline and Embase between 1 August 1990 and 31 March 2022. Study selection and participants Randomised or quasi-randomised clinical trials and observational studies on preterm infants (<37 weeks) with ROP [type 1 or severe ROP, type 2 or milder ROP, laser or anti-vascular endothelial growth factor (VEGF) treated] were included. Data extraction and synthesis We included studies on ROP and any neurocognitive or neuropsychiatric outcomes. Outcomes The primary outcomes were as follows: cognitive composite scores evaluated between the ages of 18 and 48 months by the Bayley Scales of Infant and Toddler Development (BSID) or equivalent; neurodevelopmental impairment (NDI; moderate to severe NDI or severe NDI), cerebral palsy, cognitive impairment; and neuropsychiatric or behavioural problems. The secondary outcomes were as follows: motor and language composite scores evaluated between the ages of 18 and 48 months by BSID or equivalent; motor/language impairment; and moderate/severe NDI as defined by the authors. Results In preterm infants, “any ROP” was associated with an increased risk of cognitive impairment or intellectual disability [ n = 83,506; odds ratio (OR): 2.56; 95% CI: 1.40–4.69; p = 0.002], cerebral palsy ( n = 3,706; OR: 2.26; 95% CI: 1.72–2.96; p < 0.001), behavioural problems ( n = 81,439; OR: 2.45; 95% CI: 1.03–5.83; p = 0.04), or NDI as defined by authors ( n = 1,930; OR: 3.83; 95% CI: 1.61–9.12; p = 0.002). Type 1 or severe ROP increased the risk of cerebral palsy (OR: 2.19; 95% CI: 1.23–3.88; p = 0.07), cognitive impairment or intellectual disability ( n = 5,167; OR: 3.56; 95% CI: 2.6–4.86; p < 0.001), and behavioural problems ( n = 5,500; OR: 2.76; 95% CI: 2.11–3.60; p < 0.001) more than type 2 ROP at 18–24 months. Infants treated with anti-VEGF had higher odds of moderate cognitive impairment than the laser surgery group if adjusted data (gestational age, sex severe intraventricular haemorrhage, bronchopulmonary dysplasia, sepsis, surgical necrotising enterocolitis, and maternal education) were analysed [adjusted OR (aOR): 1.93; 95% CI: 1.23–3.03; p = 0.04], but not for cerebral palsy (aOR: 1.29; 95% CI: 0.65–2.56; p = 0.45). All outcomes were adjudged with a “very low” certainty of evidence. Conclusion and relevance Infants with “any ROP” had higher risks of cognitive impairment or intellectual disability, cerebral palsy, and behavioural problems. Anti-VEGF treatment increased the risk of moderate cognitive impairment. These results support the association of ROP and anti-VEGF treatment with adverse neurodevelopmental outcomes. Systematic Review Registration https://www.crd.york.ac.uk/prospero/, identifier: CRD42022326009." @default.
- W4324375395 created "2023-03-16" @default.
- W4324375395 creator A5004965747 @default.
- W4324375395 creator A5019576860 @default.
- W4324375395 creator A5023633681 @default.
- W4324375395 creator A5035532414 @default.
- W4324375395 creator A5057669671 @default.
- W4324375395 creator A5059002831 @default.
- W4324375395 creator A5068388155 @default.
- W4324375395 creator A5090790160 @default.
- W4324375395 date "2023-03-15" @default.
- W4324375395 modified "2023-10-11" @default.
- W4324375395 title "Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis" @default.
- W4324375395 cites W1603758502 @default.
- W4324375395 cites W1731074416 @default.
- W4324375395 cites W1975855729 @default.
- W4324375395 cites W1979354799 @default.
- W4324375395 cites W1981894187 @default.
- W4324375395 cites W1987185716 @default.
- W4324375395 cites W1999885250 @default.
- W4324375395 cites W2009688205 @default.
- W4324375395 cites W2025929398 @default.
- W4324375395 cites W2031274512 @default.
- W4324375395 cites W2033795578 @default.
- W4324375395 cites W2042583708 @default.
- W4324375395 cites W2043860314 @default.
- W4324375395 cites W2049557152 @default.
- W4324375395 cites W2064147974 @default.
- W4324375395 cites W2065474663 @default.
- W4324375395 cites W2077803675 @default.
- W4324375395 cites W2083538148 @default.
- W4324375395 cites W2112554221 @default.
- W4324375395 cites W2119552229 @default.
- W4324375395 cites W2136994481 @default.
- W4324375395 cites W2140006957 @default.
- W4324375395 cites W2148952319 @default.
- W4324375395 cites W2170892587 @default.
- W4324375395 cites W2208826083 @default.
- W4324375395 cites W2269944511 @default.
- W4324375395 cites W2318076598 @default.
- W4324375395 cites W2334508015 @default.
- W4324375395 cites W2417043334 @default.
- W4324375395 cites W2490167875 @default.
- W4324375395 cites W2509254198 @default.
- W4324375395 cites W2618451894 @default.
- W4324375395 cites W2763572648 @default.
- W4324375395 cites W2769618308 @default.
- W4324375395 cites W2772531396 @default.
- W4324375395 cites W2776522050 @default.
- W4324375395 cites W2782635125 @default.
- W4324375395 cites W2793892668 @default.
- W4324375395 cites W2797371915 @default.
- W4324375395 cites W2800328168 @default.
- W4324375395 cites W2808326600 @default.
- W4324375395 cites W2885729283 @default.
- W4324375395 cites W2904625449 @default.
- W4324375395 cites W2926939937 @default.
- W4324375395 cites W2933292392 @default.
- W4324375395 cites W2944408325 @default.
- W4324375395 cites W2954062686 @default.
- W4324375395 cites W2962616584 @default.
- W4324375395 cites W2963022236 @default.
- W4324375395 cites W2969120536 @default.
- W4324375395 cites W2980758585 @default.
- W4324375395 cites W3011921546 @default.
- W4324375395 cites W3025247538 @default.
- W4324375395 cites W3027232302 @default.
- W4324375395 cites W3040855610 @default.
- W4324375395 cites W3042027825 @default.
- W4324375395 cites W3087691492 @default.
- W4324375395 cites W3100502483 @default.
- W4324375395 cites W3110709763 @default.
- W4324375395 cites W3118615836 @default.
- W4324375395 cites W3128007265 @default.
- W4324375395 cites W3133037884 @default.
- W4324375395 cites W3134496186 @default.
- W4324375395 cites W3137318674 @default.
- W4324375395 cites W3142903740 @default.
- W4324375395 cites W3144543375 @default.
- W4324375395 cites W3148465273 @default.
- W4324375395 cites W3165532368 @default.
- W4324375395 cites W3167096090 @default.
- W4324375395 cites W3182791891 @default.
- W4324375395 cites W3183558739 @default.
- W4324375395 cites W3192734349 @default.
- W4324375395 cites W3205141205 @default.
- W4324375395 cites W4200499022 @default.
- W4324375395 cites W4211151114 @default.
- W4324375395 cites W4220693344 @default.
- W4324375395 cites W4308909895 @default.
- W4324375395 doi "https://doi.org/10.3389/fped.2023.1055813" @default.
- W4324375395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37009271" @default.
- W4324375395 hasPublicationYear "2023" @default.
- W4324375395 type Work @default.
- W4324375395 citedByCount "1" @default.
- W4324375395 countsByYear W43243753952023 @default.
- W4324375395 crossrefType "journal-article" @default.
- W4324375395 hasAuthorship W4324375395A5004965747 @default.
- W4324375395 hasAuthorship W4324375395A5019576860 @default.
- W4324375395 hasAuthorship W4324375395A5023633681 @default.